What Is Efficacy of Chloroquine/Hydroxychloroquine in Clinical Cure of SARS-CoV-2? Evidence from an Iranian Population

Novel coronavirus which is known as sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerged in December 2019 from Wuhan, Hubei Province, China for the first time. The SARS-Cov 2 (The coronavirus disease 2019) is etiological cause of a viral sever pneumonia (1); however, The WHO is announced this disease as pandemic in 11th March 2020, due to its quickly spread and increasing number of COVID-19 patients throughout the worldwide (2, 3). There is an increasing number of people death related to COVID-19 which can be result from limitation in the efficient therapeutic options against COVID-19 (4). Introduction of efficient and safe therapeutic agents for COVID-19 is considered as one of the major global concern in this regard (5, 6). There is numerous treatment option for COVID-19 which are including teicoplanin, chloroquine/hydroxychloroquine, remdesivir, lopinavir/ritonavir, oseltamivir, umifenovir, ribavirin, favipiravir, IFN-alpha, mycophenolic acid, corticosteroids, as well as, angiotensin-converting enzyme 2 gene-based peptides; although, there is remains a question that what is therapeutic agents has more virological and clinical efficacy without serious side-effects?? (7, 8).

What Is Efficacy of Chloroquine/Hydroxychloroquine in Clinical Cure of SARS-CoV-2? Evidence from an Iranian Population Keywords:

Iran , Chloroquine , COVID-19 , SARS-CoV 2 , Hydroxychloroquine